Components:
Method of action:
Treatment option:
Medically reviewed by Fedorchenko Olga Valeryevna, PharmD. Last updated on 21.03.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
Top 20 medicines with the same treatments:
For dilution of solutions for nebulisation.
Adults, children and elderly: use as directed by the physician.
0.9% w/v Sodium Chloride B Braun is only to be used as a diluent for diluting products for nebulisation and should not be used on its own. It should not be taken orally or administered parenterally.
Each ampoule contains 2.5 ml of solution.
Refer to the patient information leaflet of the nebulised product to be diluted that your physician has prescribed you for detailed instructions on use of this solution as a diluent. To ensure accurate dosing it is recommended that a dosing syringe is used if necessary.
Method of Administration: By inhalation from a suitable nebuliser or an intermittent positive pressure ventilator after the single dose ampoule has been opened and its contents transferred to the nebuliser chamber. Administration should be in accordance with the manufacturer's instructions for the device.
1. Prepare the nebuliser by following the manufacturer's instructions and the advice of your doctor.
2. The nebulised product to be diluted should be introduced into the nebuliser chamber as instructed in the appropriate patient information leaflet.
3. Carefully separate a new saline ampoule from the strip. Never use an ampoule that has been opened already.
3. Open the ampoule by simply twisting off the top, always taking care to hold it in an upright position.
4. Squeeze the contents of the plastic ampoule or use a dosing syringe as required into the nebuliser chamber and swirl gently to mix.
5. Assemble the nebuliser and use it as directed by your doctor.
6. After nebulisation, clean the nebuliser according to the manufacturer's instructions. It is important that the nebuliser is kept clean.
As the single dose units contain no preservatives it is important that the contents are used immediately after opening and a fresh ampoule is used for each administration to avoid microbial contamination. Partly used, opened or damaged single dose units should be discarded.
Any solution remaining in the nebuliser chamber should be discarded.
The solution should not be administered orally or parenterally.
Do not use unless the product is clear and the pack intact. Discard any surplus after use. 0.9% w/v Sodium Chloride B Braun should be used with a nebuliser, only under the direction of a physician. Patients using nebuliser solutions at home should be warned that if the usual relief is diminished or the usual duration of action reduced, they should consult their doctor.
Not known.
0.9% w/v Sodium Chloride B Braun is not expected to cause any undesirable effects in normal use.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme; website: www.mhra.gov.uk/yellowcard
Substantial oral ingestion may require the use of a diuretic to remove excess sodium.
Isotonic (0.9% w/v) sodium chloride solution is widely used for dilution purposes.
Not applicable
There are no findings of relevance to the prescriber other than those already mentioned elsewhere in the SPC. Please refer to the product to be reconstituted.
Not applicable
No special requirements.
- Use of adrenaline continuous infusion to treat hypotension during general anaesthesia in a cow and a calf
- Design and in vivo evaluation of a microparticulate depot formulation of buprenorphine for veterinary use
- In vitroTargetability Validation of Peptide-Functionalized Mesoporous Silica Nanoparticles in the Presence of Serum Proteins
- Affinity Purification of Label-free Tubulins from XenopusEgg Extracts
- In Vivo Validation of Spray-Dried Mesoporous Bioactive Glass Microspheres Acting as Prolonged Local Release Systems for BMP-2 to Support Bone Regeneration
- Enzyme Stability in Nanoparticle Preparations Part 1: Bovine Serum Albumin Improves Enzyme Function
- Advillin is a tuft cell marker in the mouse alimentary tract
- Loss of the Extracellular Matrix Molecule Tenascin-C Leads to Absence of Reactive Gliosis and Promotes Anti-inflammatory Cytokine Expression in an Autoimmune Glaucoma Mouse Model
- The Importance of Evaluating the Lot-to-Lot Batch Consistency of Commercial Multi-Walled Carbon Nanotube Products
- 56 thEASD Annual Meeting of the European Association for the Study of Diabetes
- Heparin Anticoagulant for Human Bone Marrow Does Not Influence In Vitro Performance of Human Mesenchymal Stromal Cells
- Lysophosphatidic acid improves corneal endothelial density in tissue culture by stimulating stromal secretion of interleukin‐1β
- Modeling mosquito-borne and sexual transmission of Zika virus in an enzootic host, the African green monkey
- Antioxidant Effects of Walnut ( Juglans regiaL.) Kernel and Walnut Septum Extract in a D-Galactose-Induced Aging Model and in Naturally Aged Rats
- A randomized, controlled, double-blind crossover study on the effects of isoeffective and isovolumetric intravenous crystalloid and gelatin on blood volume, and renal and cardiac hemodynamics
- Sonic irrigant activation for root canal disinfection: power modes matter!
- An off-the-shelf artificial cardiac patch improves cardiac repair after myocardial infarction in rats and pigs
- A novel histidine–tryptophan–ketoglutarate formulation ameliorates intestinal injury in a cold storage and ex vivowarm oxygenated reperfusion model in rats
- Regulatory T Cell Extracellular Vesicles Modify T-Effector Cell Cytokine Production and Protect Against Human Skin Allograft Damage
- The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross‐species comparison of its cytochrome P450 induction pattern
However, we will provide data for each active ingredient